ABL-104

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameABL-104
Drug Alias NameABL-104YH-32364
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsEpidermal growth factor receptor erbB1 antagonists +[4] 
TargetsEpidermal growth factor receptor erbB1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbl Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio IncYuhan Corp
Inactive CompaniesN/A
Active IndicationsSolid tumoursHead and Neck NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A